Navigation Links
PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors

Larry G. Pickering Resigns from the Board of Directors

NEW YORK, Feb. 12 /PRNewswire/ -- PeriCor Therapeutics today announced the appointment of K. Tucker Andersen as a director of the Company's Board of Directors effective February 7, 2008. Mr. Andersen is a retired portfolio manager and security analyst and the sole proprietor of the consulting firm Above All Advisors, LLC. The Company also announced that on February 1, 2008, Larry G. Pickering resigned as a director of the Company.

"We are very pleased that Tucker has agreed to join the PeriCor Board of Directors," stated Richard R. Stover, President and CEO of PeriCor Therapeutics. "Tucker brings a wealth of financial and corporate experience to the company. His extensive background as an investor and director of a variety of businesses will be an asset to the development of PeriCor Therapeutics." Mr. Stover further stated, "We would also like to thank Larry Pickering for his dedication and service to the Company. Mr. Pickering made valuable contributions to the strategic direction of PeriCor during his time as a director and we wish him well in the future."

Before founding Above All Advisors, LLC, Mr. Andersen was co-Managing Partner and Chief Investment Strategist for Cumberland Associates. He currently serves as chairman of Artificial Cell Technologies, a biotechnology-nanotechnology venture stage firm and serves on the boards of the International Foundation for Research in Experimental Economics (headed by Nobel Laureate Vernon Smith), the Cato Institute, GOPAC, the Questech Corporation, the Foundation for the Advancement of Monetary Education, and the Warren, Connecticut Congregational Church. He is also on the advisory board of Brook Venture Partners, and has recently become a Founding Partner of Value Insight Partners, a fund of funds investing in a select group of value oriented hedge funds with diverse investment strategies. While retired from his position as vice-president of the board of the Phillips Exeter Academy, he still serves as a member of Exeter's investment committee which he formerly chaired. Mr. Andersen is a Chartered Financial Analyst and Associate Member of the Society of Actuaries. He received his Bachelor's degree in Quantitative Studies from Wesleyan University and is the recipient of Wesleyan's Distinguished Alumnus Award and of the Founder's Day Award from Exeter.

About PeriCor Therapeutics

PeriCor Therapeutics, Inc. is a privately-held specialty biopharmaceutical company focused on the development and commercialization of a new class of medicines, adenosine regulating agents, to prevent the perioperative complications of surgery and improve the treatment and outcomes of acute cardiovascular care.

SOURCE PeriCor Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
3. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
4. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
5. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
6. Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
7. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
8. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
9. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
10. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
11. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
Post Your Comments:
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... Supplyframe, the Industry Network for electronics ... Lab . Located in Pasadena, Calif., the Design Lab’s mission is to bring ... designed, built and brought to market. , The Design Lab is Supplyframe’s physical ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... , June 23, 2016 On Wednesday, ... at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged ... closed at 2,085.45, down 0.17%. has initiated coverage on ... ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals ... (NASDAQ: BIND ). Learn more about these stocks ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: ... for financial services, but it also plays a fundamental part ...
Breaking Biology News(10 mins):